Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products

@inproceedings{Hinsbergh1990ProgressOF,
  title={Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products},
  author={Victor W.M. van Hinsbergh and Kenneth A. Bauer and Teake Kooistra and Cornelis Kluft and Gerard Dooijewaard and Matthew Sherman and Willem Nieuwenhuizen},
  year={1990}
}
Several investigators have reported that tumor necrosis factor (TNF) can alter the production of plasminogen activator type-1 (PAI-1) and plasminogen activators (PAs) by endothelial cells in vitro. We have examined the in vivo effects of recombinant human TNF administration on fibrinolysis as assessed by parameters in plasma during a 24-hour period of continuous TNF infusion to 17 cancer patients with active disease. The plasma levels of PAI activity increased sevenfold after 3 and 24 hours of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Colistin dampens fibrinolysis and endothelial activation during endotoxaemia

  • Thrombosis and haemostasis
  • 2017
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Principles of pulmonary protection in heart surgery

VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED